Inhibikase Therapeutics Inc. Company Profile
NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Inhibikase Therapeutics at a glance
Inhibikase Therapeutics Inc. (NASDAQ: IKT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Wilmington, DE. Inhibikase Therapeutics is led by Mr. Mark T. Iwicki and employs about 35 people. The company's shares have traded publicly since 2020.
At a market capitalization of $182.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001750149, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Inhibikase Therapeutics do?
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Business description based on the company's public filings.
Company information
- Legal name
- Inhibikase Therapeutics Inc.
- Ticker
- NASDAQ: IKT
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Mark T. Iwicki
- Employees
- 35
- Headquarters
- 1000 N. West Street, Wilmington, DE, United States
- Phone
- 302 295 3800
- Website
- inhibikase.com
- IPO year
- 2020
- Market cap
- $182.35M
- SEC CIK
- 0001750149
- Latest annual report
- 10-K · Mar 26, 2026
Companies similar to Inhibikase Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARTVArtiva Biotherapeutics Inc. | 3.78 | -1.31% | $186.85M | vs IKT |
| CGENCompugen Ltd. | 1.84 | -2.13% | $174.29M | vs IKT |
| LCTXLineage Cell Therapeutics Inc. | 0.7719 | -5.87% | $195.26M | vs IKT |
| CABACabaletta Bio Inc. | 0.9361 | -7.32% | $201.94M | vs IKT |
| IPSCCentury Therapeutics Inc. | 1.17 | -11.74% | $211.56M | vs IKT |
| PALIPalisade Bio Inc. | 0.8399 | -9.24% | $150.74M | vs IKT |
| ALLOAllogene Therapeutics Inc. | 0.6277 | -5.88% | $217.48M | vs IKT |
| STROSutro Biopharma Inc. | 8.60 | -1.38% | $142.77M | vs IKT |